StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3012% below fair value
$28.88−1.06 (-3.54%)

Close on Nov 16, 2026Market cap $1.49BP/E –Yield 0.00%

Immunocore profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Immunocore's profit margin for the twelve months ending Jun 30, 2026 was -4.2%. For fiscal 2025 it was -8.9%, against -16.5% the year before. The highest annual figure on record is -8.9% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-8.9%+7.6
FY2024Dec 31, 2024-16.5%+5.7
FY2023Dec 31, 2023-22.2%+8.0
FY2022Dec 31, 2022-30.1%+463.3
FY2021Dec 31, 2021-493.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-0.7%+9.8
Q1 FY2026Mar 31, 202612.2%+6.8
Q4 FY2025Dec 31, 2025-28.8%−0.5
Q3 FY2025Sep 30, 2025-0.2%−11.1
Q2 FY2025Jun 30, 2025-10.5%+4.9
Q1 FY2025Mar 31, 20255.4%+40.0
Q4 FY2024Dec 31, 2024-28.3%−0.2
Q3 FY2024Sep 30, 202410.9%+9.5
Q2 FY2024Jun 30, 2024-15.4%+13.1
Q1 FY2024Mar 31, 2024-34.7%+0.9
Q4 FY2023Dec 31, 2023-28.1%–
Q3 FY2023Sep 30, 20231.4%–
Q2 FY2023Jun 30, 2023-28.5%–
Q1 FY2023Mar 31, 2023-35.6%–

More Immunocore figures

See a number that looks wrong?